TOKYO -- A new type of coronavirus vaccine that requires less than one-tenth the dosage of existing shots made by Pfizer and others is nearing clinical trials in Japan, with the developer hoping to counter new variants of the virus.
The vaccine uses messenger RNA , which is also used in the Pfizer/BioNTech vaccine. The messenger RNA instructs cells to produce a protein found in the coronavirus. This protein stimulates an immune response against the virus. VLP estimates that the dosage required per person would be 1 to 10 micrograms, which is 1% to 10% the amount required for other RNA-based vaccines. In theory, Japan's entire population would require about 130 grams to 1,300 grams.
VLP was founded in 2013 by Wataru Akahata, a vaccine researcher at the U.S. National Institutes of Health. The startup is backed by investors including Japanese trading house Sojitz and Miyako Capital. It has also been supported by the Japan Agency for Medical Research and Development since fiscal 2020.
NikkeiAsia 米国の新興企業が今夏、日本で小容量「COVID」ワクチンの人体実験を実施 ? 動物実験で南アフリカとブラジルの亜種に有効 このワクチンは自己増殖するようですが、 『東京医科歯科大学の板高圭司教授は「mRNAの自己複製が過度に続くと、予期せぬ副作用を引き起こす危険性がある」と述べた』
NikkeiAsia あら 人体実験
NikkeiAsia これは投与回数も1回等と少なくて済むのでしょうか?
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: nikkei - 🏆 135. / 51 続きを読む »
ソース: nikkei - 🏆 135. / 51 続きを読む »
ソース: nikkei - 🏆 135. / 51 続きを読む »
ソース: gigazine - 🏆 80. / 51 続きを読む »